| answer text |
<p><del class="ministerial">The Government has considered the link between changes
to the volume-based rebate payments in our medicine pricing schemes and various kinds
of investment, along with any associated impacts on employment in the life sciences
industry in the United Kingdom, in our impact assessment of recent updates to the
statutory scheme for branded medicines pricing, which operates alongside the voluntary
scheme for branded medicines pricing and access (VPAS).</del></p><p><del class="ministerial">The
Government’s 2023 impact assessment of updates to the statutory scheme is available
at the following link:</del></p><p><del class="ministerial"><a href="https://www.gov.uk/government/consultations/proposed-update-to-the-2023-statutory-scheme-to-control-the-costs-of-branded-health-service-medicines"
target="_blank">https://www.gov.uk/government/consultations/proposed-update-to-the-2023-statutory-scheme-to-control-the-costs-of-branded-health-service-medicines</a></del></p><p><del
class="ministerial">With regard to the impact of medicine price regulation schemes
on the level of foreign direct investment into the UK’s life sciences research and
development, the evidence on this issue is uncertain. The impact assessment considered
this issue, and sets out the Government’s assessment that, while price regulation
schemes such as VPAS may be a consideration in the decision to locate such investments,
these are complex decisions based on multiple factors. Supply side factors such as
the availability of skilled labour are considered likely to be of greater significance.</del></p><p><del
class="ministerial">With regard to the impact of price regulation on the placement
of clinical trials in the UK, the Government’s assessment is that price control schemes
in general are more likely to impact decisions about the location of late-stage than
early-stage trials, as the location of late-stage trials may be more influenced by
commercial considerations about where to launch a new medicine. However, VPAS includes
strong commercial incentives to launch new products in the form of freedom of list
pricing and exemptions from payments for innovative medicines containing a new active
substance.</del></p><p><ins class="ministerial"> <p><ins class="ministerial">The information
requested is publicly available and can be accessed here: </ins></p><p><ins class="ministerial">https://digital.nhs.uk/data-and-information/publications/statistical/general-and-personal-medical-services/31-december-2022.</ins></p><p>
</p><p><ins class="ministerial">Notes</ins></p><p> </p><p><ins class="ministerial">·
Data includes estimates for practices that did not provide fully valid staff records.</ins></p><p><ins
class="ministerial">· In December 2022, 2.1% of fully qualified GP FTE was estimated
where practices had not provided fully valid staff records.</ins></p><p><ins class="ministerial">·
Before July 2021, data was only available quarterly for the following months: March,
June, September and December.</ins></p><p><ins class="ministerial">· Full-time equivalent
(FTE) refers to the proportion of full time contracted hours that the post holder
is contracted to work. 1 would indicate they work a full set of hours (37.5), 0.5
that they worked half time.</ins></p><p><ins class="ministerial">TARGET DATE 09/02/2023</ins></p><p><ins
class="ministerial">· Figures shown do not include staff working in prisons, army
bases, educational establishments, specialist care centres including drug rehabilitation
centres, walk-in centres and other alternative settings outside of traditional general
practice such as urgent treatment centres and minor injury units.</ins></p><p><ins
class="ministerial">· Figures include GP partners, salaried GPs, GP retainers and
GP regular locums.</ins></p></ins></p>
|
|
